Influence of dasatinib and anti-OX40 treatment on the tumor-infiltrating lymphocytes. (A) Effect of dasatinib and anti-OX40 on levels of the P1A-specific T cells in the blood. (B) Total numbers of CD8⁺ T cells and the ratios of CD8⁺ T-cell number/tumor weight (for CD8⁺ T-cell total number, vehicle + IgG vs vehicle + anti-OX40: ***P = .0007, dasatinib + IgG vs dasatinib + anti-OX40: *P = .0250, vehicle + IgG vs dasatinib + anti-OX40: *P = .0165; for CD8⁺ T-cell number/gram, vehicle + IgG vs vehicle + anti-OX40: ***P = .0002, dasatinib + IgG vs dasatinib + anti-OX40: *P = .0234, vehicle + IgG vs dasatinib + anti-OX40: **P = .0076). (C) Total numbers of P1A tetramer⁺ CD8⁺ T cells and the ratios of P1A tetramer⁺CD8⁺ T-cell number/weight (for P1A tetramer⁺ T-cell total number, vehicle + anti-OX40 vs dasatinib + anti-OX40: *P = .0110, dasatinib + IgG vs dasatinib + anti-OX40: **P = .0078, vehicle + IgG vs dasatinib + anti-OX40: **P = .0024; for P1A tetramer⁺ T-cell number/gram, vehicle + anti-OX40 vs dasatinib + anti-OX40: *P = .0265, dasatinib + IgG vs dasatinib + anti-OX40: *P = .0507, vehicle + IgG vs dasatinib + anti-OX40: *P = .0229). (D) Total numbers of IFN-γ⁺ CD8⁺ T cells and the ratios of IFN-γ⁺ CD8⁺ T-cell number/tumor weight (for IFN-γ⁺ T-cell total number, vehicle + anti-OX40 vs dasatinib + anti-OX40: ***P < .0001, dasatinib + IgG vs dasatinib + anti-OX40: ***P < .0001, vehicle + IgG vs dasatinib + anti-OX40: ***P < .0001; for IFN-γ⁺ T-cell number/gram, vehicle + anti-OX40 vs dasatinib + anti-OX40: *P = .0195, dasatinib + IgG vs dasatinib + anti-OX40: *P = .0505, vehicle + IgG vs dasatinib + anti-OX40: *P = .0220).